TMSxDCS: Medicinal improvement of brain stimulation for depression.
Key facts
- Where
- Maastricht, HollandiaSee the 2 sites
- Phase
- 2. fázis
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Hollandia
- Brain ModulationMaastricht, HollandiaToborzás még nem indult
- Universiteit MaastrichtMaastricht, HollandiaToborzás még nem indult
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Universiteit Maastricht
- Trial code
- EU 2025-521166-95-00
- Record updated
- 2026. szeptember 21.
- Original description
The primary objective of this study is to investigate the antidepressive effect of augmenting a single day of accelerated transcranial magnetic stimulation (TMS) with D-cycloserine (DCS).Read full original descriptionShow less
TMSxDCS: Pharmacologically augmenting transcranial magnetic stimulation for depression
The primary objective of this study is to investigate the antidepressive effect of augmenting a single day of accelerated transcranial magnetic stimulation (TMS) with D-cycloserine (DCS).
Inclusion: A primary diagnosis of MDD, with a current moderate to severe depressive episode (score of >20 on the MADRS); Age between 18-65 years old; A diagnosis of moderate to severe measures of treatment resistant depression (TRD) and have tried at least 2 types of antidepressant medication without sufficient result.
Exclusion: Any change in antidepressant treatment (medication, psychotherapy) 4 weeks prior to enrollment; Has a cochlear implant; Metal implants near (<10 cm away from coil) the head including: - Aneurysm clips / coils - Any medical implant containing metal near the head - Metal stents in the brain - Shrapnel or bullet fragments - Implanted vagus nerve or deep brain stimulators, Electrodes for monitoring brain activity; Current scheduled use of benzodiazepines (as needed use is permitted, except for the day prior to treatment); Current use of any of the following medications: Olanzapine, clozapine, ethionamide, isoniazid; Primary psychiatric diagnosis other than MDD; A history of bipolar disorder; A history of psychosis; A history of schizophrenia; A history of renal insufficiency; Current substance abuse disorder; Pregnancy upon inclusion or during the study period, though women with childbearing potential will be included into the study.